



[www.dynapulse.com](http://www.dynapulse.com), Preventagen, Inc.™  
2100 Hawley Drive, Vista, California USA

August 8, 2013

To: Prof. Antonio Delgado-Almeida, MD, FAHA, FACC  
Head, Clinical Research Unit and Ion Transport Laboratory  
University of Carabobo, Valencia, Venezuela

Re. New paradigm on Cardiovascular Diseases - DynaPulse Hemodynamic Profiling and Red blood Cell Potassium (RBC-K) Physiology & Disorders

Dear Dr. Delgado:

Thank you for your letter of July 30, 2013, and the included information, comments, clinical studies and references, etc. that summarized the past, current and future developments and researches in improving the management of hypertension and cardiovascular diseases (CVD).

Your works, clinical observations, of RBC-K physiology and disorder together with the analysis of DynaPulse hemodynamic parameters and supra-systolic waveform on subjects with hypertension and CVD, as I had mentioned to you and other researchers before, is remarkable, which describes the phenomena reflecting the physiology of interaction of Macro- (DynaPulse hemodynamics) and Micro-Circulations of human vascular system associating to the cause and origin of hypertension. Applying these information to treat hypertension and CVD is NOBLE and the most advanced method available today. It shall be the direction of future researches in managing hypertension and CVD.

The article "How to manage a worldwide patient population of 1.5 billion hypertension" you sent me and talked about a lot tells that you have not only devoted your life in hypertension researches, but also in helping billions of people suffering with hypertension and CVD, which is also NOBLE, like Dr. Giuseppe Mancia, Dr. Sverre Kjeldsen and many other doctors, I admired and respected the most.

As I had mentioned to you before, your observations and clinical data that linked the Macro- and Micro-circulation on hypertension patients is essential to help future development of a completed physical model for explaining the complicated physiology of human circulation system and the causes of hypertension and CVD. When that is done, it will be the most important contribution to the future development of an advanced treatment or management of hypertension and CVD in medicine. Your vision of "Our goal in CV medicine is Normal BP and Hemodynamics, and Normal RBC-K" shall become possible and the "Standard of Care" in hypertension management.

Sincerely,

Shiu-Shin Chio, PhD, CEO and Founder  
DynaPulse/Preventagen, Inc., 2100 Hawley Drive, Vista, CA 92084 USA  
Tel: (760) 842-8278 Fax: (760) 758-9425 Email: [ssc@dynapulse.com](mailto:ssc@dynapulse.com)